Q-omics provides the consensus-scored MIR7850 profile across patient tissues and cancer cell-line models. MIR7850 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR7850 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR7850 RNA expression shows 9,454 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUAD, THCA, and LAML as cancer lineages where MIR7850 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7850 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7850 survival associations across molecular data types. MIR7850 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7850 RNA expression–survival associations across cancer types. High MIR7850 expression shows unfavorable associations in KIRP, KIRC, HNSC and DLBC, but favorable associations in LUAD and OV. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR7850 RNA expression.
This table summarizes MIR7850 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7850. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7850 shows lower tumor expression in THCA. The THCA box plot shows higher MIR7850 RNA expression in normal versus tumor tissue (log2 FC = −0.228, t-test p = .001).
This table shows molecular features associated with MIR7850 in patient tissues and cancer cell lines. In patient samples, MIR7850 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
